All In Biotech

Drug Trial Radar · NCT05477576

Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy

Phase 1b/3 Global, Randomized, Controlled, Open-label Trial Comparing Treatment With RYZ101 to Standard of Care Therapy in Subjects With Inoperable, Advanced, SSTR+, Well-differentiated GEP-NETs That Have Progressed Following Prior 177Lu-SSA Therapy

Last checked: Nov 19, 2026Latest source record: Oct 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 343 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

343

Actual

Start

Mar 24, 2022

Primary completion

Dec 2026

Study completion Dec 2030

Sponsor

Lead sponsor
RayzeBio, Inc.Industry
Sponsor type
Industry
First posted
Jul 28, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study aims to determine the safety, pharmacokinetics (PK) and recommended Phase 3 dose (RP3D) of RYZ101 in Part 1, and the safety, efficacy, and PK of RYZ101 compared with investigator-selected standard of care (SoC) therapy in Part 2 in subjects with inoperable, advanced, well-differentiated, somatostatin receptor expressing (SSTR+) gastroenteropancreatic neuroendocrine tumors (GEP-NETs) that have progressed following treatment with Lutetium 177-labelled somatostatin analogue (177Lu-SSA) therapy, such as 177Lu-DOTATATE or 177Lu-DOTATOC (177Lu-DOTATATE/TOC), or 177Lu-high affinity \[HA\]-DOTATATE.

Conditions

  • GEP-NET
  • Gastroenteropancreatic Neuroendocrine Tumor
  • Gastroenteropancreatic Neuroendocrine Tumor Disease
  • Neuroendocrine Tumors
  • Carcinoid
  • Carcinoid Tumor
  • Pancreatic NET

Interventions

  • RYZ101Drug

    RP3D as determined in Phase 1b

  • EverolimusDrug

    Everolimus

  • SunitinibDrug

    Sunitinib

  • OctreotideDrug

    High-dose octreotide

  • LanreotideDrug

    Lanreotide

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1b: RP3DTime frame: 56 days of study treatment
  2. Phase 3: PFS as determined by BICRTime frame: After the target number of 143 PFS events have occurred

Locations

54 sites in 8 countries. Site status is shown where the registry gives one.

  • Research Facility

    Phoenix, Arizona

  • Research Facility

    Duarte, California

  • Research Facility

    Irvine, California

  • Research Facility

    Los Angeles, California

  • Research Facility

    Palo Alto, California

  • Research Facility

    San Francisco, California

  • Research Facility

    New Haven, Connecticut

  • Research Facility

    Washington D.C., District of Columbia

  • Research Facility

    Jacksonville, Florida

  • Research Facility

    Miami, Florida

  • Research Facility

    Tampa, Florida

  • Research Facility

    Atlanta, Georgia

  • Research Facility

    Iowa City, Iowa

  • Research Facility

    Lexington, Kentucky

  • Research Facility

    Glen Burnie, Maryland

  • Research Facility

    Boston, Massachusetts

  • Research Facility

    Boston, Massachusetts

  • Research Facility

    Troy, Michigan

  • Research Facility

    Rochester, Minnesota

  • Research Facility

    St Louis, Missouri

  • Research Facility

    Omaha, Nebraska

  • Research Facility

    New York, New York

  • Research Facility

    New York, New York

  • Research Facility

    Cleveland, Ohio

  • Research Facility

    Columbus, Ohio

  • Research Facility

    Portland, Oregon

  • Research Facility

    Philadelphia, Pennsylvania

  • Research Facility

    Pittsburgh, Pennsylvania

  • Research Facility

    Nashville, Tennessee

  • Research Facility

    Houston, Texas

  • Research Facility

    Salt Lake City, Utah

  • Research Facility

    Seattle, Washington

  • Research Facility

    Brussels, Belgium

  • Research Facility

    Leuven, Belgium

  • Research Facility

    Roeselare, Belgium

  • Research Facility

    Brasília, Brazil

  • Research Facility

    Rio de Janeiro, Brazil

  • Research Facility

    São Paulo, Brazil

  • Research Facility

    London, Ontario, Canada

  • Research Facility

    Toronto, Ontario, Canada

Showing 40 of 54 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.